Invst LLC Acquires 218 Shares of Johnson & Johnson (NYSE:JNJ)

Invst LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 11.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,083 shares of the company’s stock after purchasing an additional 218 shares during the period. Invst LLC’s holdings in Johnson & Johnson were worth $305,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Eagle Asset Management Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $1,446,000. CIBC Private Wealth Group LLC boosted its holdings in shares of Johnson & Johnson by 0.6% during the 4th quarter. CIBC Private Wealth Group LLC now owns 717,254 shares of the company’s stock valued at $112,422,000 after acquiring an additional 3,938 shares in the last quarter. Royal London Asset Management Ltd. boosted its holdings in shares of Johnson & Johnson by 3.4% during the 4th quarter. Royal London Asset Management Ltd. now owns 1,619,599 shares of the company’s stock valued at $253,856,000 after acquiring an additional 53,116 shares in the last quarter. ROI Financial Advisors LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $447,000. Finally, Edge Capital Group LLC lifted its holdings in Johnson & Johnson by 12.0% during the 4th quarter. Edge Capital Group LLC now owns 111,673 shares of the company’s stock worth $17,504,000 after buying an additional 12,000 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on JNJ. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. TD Securities cut their target price on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Finally, TD Cowen cut their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $162.02 on Tuesday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The business’s 50 day simple moving average is $162.30 and its 200 day simple moving average is $154.18. The company has a market cap of $389.93 billion, a price-to-earnings ratio of 10.10, a PEG ratio of 2.69 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.80 earnings per share. Sell-side analysts forecast that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were issued a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. Johnson & Johnson’s payout ratio is currently 30.92%.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.